AGIO vs. ARQT

Last updated Aug 1, 2026

AGIO (Agios Pharmaceuticals, Inc.) and ARQT (Arcutis Biotherapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, AGIO returned -8.99%/yr vs 2.86%/yr for ARQT. Their 0.36 correlation means their historical movements had little consistent relationship.

Performance

AGIO vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, AGIO achieves a 10.29% return, which is significantly higher than ARQT's -7.51% return.

AGIO

• 1D: -8.34%
• 1M: -20.12%
• 6M: 9.40%
• YTD: 10.29%
• 1Y: -14.23%
• 3Y*: 3.87%
• 5Y*: -8.99%
• 10Y*: -3.95%
• ALL TIME*: 0.27%

ARQT

• 1D: -4.04%
• 1M: 4.07%
• 6M: 5.87%
• YTD: -7.51%
• 1Y: 87.96%
• 3Y*: 36.46%
• 5Y*: 2.86%
• 10Y*: —
• ALL TIME*: 2.38%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
AGIO Agios Pharmaceuticals, Inc.	$51.87M	$46.01M	$36.85M
ARQT Arcutis Biotherapeutics, Inc.	$31.41M	$36.97M	$43.61M

AGIO vs. ARQT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
AGIO Agios Pharmaceuticals, Inc.	10.29%	-17.16%	47.55%	-20.69%	-14.57%	-24.14%	-16.75%
ARQT Arcutis Biotherapeutics, Inc.	-7.51%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	22.04%

Correlation

The correlation between AGIO and ARQT is 0.35, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.35
Correlation (3Y) Balances recent behavior with more history.	0.33
Correlation (5Y) Shows whether the relationship held over a longer period.	0.37
Correlation (All Time) Calculated using the full available price history since Jan 31, 2020	0.36

Fundamentals

Market Cap AGIO : $1.79B ARQT : $3.36B
EPS AGIO : -$7.01 ARQT : -$0.02
PS Ratio AGIO : 17.92 ARQT : 8.57
PB Ratio AGIO : 1.74 ARQT : 18.32
Total Revenue (TTM) AGIO : $98.34M ARQT : $415.62M
Gross Profit (TTM) AGIO : $86.46M ARQT : $377.98M
EBITDA (TTM) AGIO : -$418.15M ARQT : $12.21M

Return for Risk

AGIO vs. ARQT — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

AGIO

AGIO Risk / Return Rank: 36
AGIO Sharpe Ratio Rank: 33
AGIO Sortino Ratio Rank: 39
AGIO Omega Ratio Rank: 43
AGIO Calmar Ratio Rank: 31
AGIO Martin Ratio Rank: 32

ARQT

ARQT Risk / Return Rank: 82
ARQT Sharpe Ratio Rank: 85
ARQT Sortino Ratio Rank: 84
ARQT Omega Ratio Rank: 82
ARQT Calmar Ratio Rank: 81
ARQT Martin Ratio Rank: 79

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

AGIO vs. ARQT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	AGIO	ARQT	Difference
Sharpe ratio: Return per unit of total volatility	-0.25	1.47	-1.72
Sortino ratio: Return per unit of downside risk	0.25	2.27	-2.02
Omega ratio: Gain probability vs. loss probability	1.05	1.28	-0.23
Calmar ratio: Return relative to maximum drawdown	-0.38	2.26	-2.64
Martin ratio: Return relative to average drawdown	-0.66	5.02	-5.68

AGIO vs. ARQT - Sharpe Ratio Comparison

The current AGIO Sharpe Ratio is -0.25, which is lower than the ARQT Sharpe Ratio of 1.47. The chart below compares the historical Sharpe Ratios of AGIO and ARQT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

AGIO vs. ARQT - Drawdown Comparison

The maximum AGIO drawdown since its inception was -87.36%, smaller than the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for AGIO and ARQT.

Drawdown Indicators

	AGIO	ARQT	Difference
Max Drawdown Largest peak-to-trough decline	-87.36%	-95.02%	+7.66%
Max Drawdown (1Y) Largest decline over 1 year	-50.89%	-37.50%	-13.39%
Max Drawdown (3Y) Largest decline over 3 years	-63.76%	-81.28%	+17.52%
Max Drawdown (5Y) Largest decline over 5 years	-65.73%	-93.17%	+27.44%
Max Drawdown (10Y) Largest decline over 10 years	-82.86%	—	—
Current Drawdown Current decline from peak	-77.76%	-27.37%	-50.39%
Average Drawdown Average peak-to-trough decline	-59.00%	-49.60%	-9.40%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.43%	16.82%	+12.61%

Volatility

AGIO vs. ARQT - Volatility Comparison

Agios Pharmaceuticals, Inc. (AGIO) has a higher volatility of 22.65% compared to Arcutis Biotherapeutics, Inc. (ARQT) at 12.05%. This indicates that AGIO's price experiences larger fluctuations and is considered to be riskier than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AGIO	ARQT	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.65%	12.05%	+10.60%
Volatility (6M) Calculated over the trailing 6-month period	45.99%	37.39%	+8.60%
Volatility (1Y) Calculated over the trailing 1-year period	77.63%	57.52%	+20.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	59.62%	71.75%	-12.13%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	56.97%	76.34%	-19.37%

Dividends

AGIO vs. ARQT - Dividend Comparison

Neither AGIO nor ARQT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both AGIO and ARQT in my portfolio?

AGIO and ARQT have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, AGIO or ARQT?

AGIO has higher volatility (22.65%) compared to ARQT (12.05%). In terms of maximum drawdown, AGIO dropped -87.36% vs ARQT's -95.02%.

Which has better risk-adjusted returns?

ARQT currently has the higher Sharpe Ratio (1.47 vs -0.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.